Amgen Inc (AMGN)vsStryker Corporation (SYK)
AMGN
Amgen Inc
$331.70
+0.79%
HEALTHCARE · Cap: $177.71B
SYK
Stryker Corporation
$285.47
-2.98%
HEALTHCARE · Cap: $112.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Amgen Inc generates 47% more annual revenue ($37.22B vs $25.27B). AMGN leads profitability with a 21.0% profit margin vs 13.2%. SYK appears more attractively valued with a PEG of 1.39. AMGN earns a higher WallStSmart Score of 62/100 (C+).
AMGN
Buy62
out of 100
Grade: C+
SYK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.2%
Fair Value
$321.89
Current Price
$331.70
$9.81 premium
Margin of Safety
-10.9%
Fair Value
$265.23
Current Price
$285.47
$20.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 101 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Trading at 19.5x book value
4.4% earnings growth
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.39 suggests the stock is reasonably priced for its growth.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AMGN profiles as a mature stock while SYK is a value play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.81 — expect wider price swings.
AMGN is growing revenue faster at 5.8% — sustainability is the question.
AMGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
AMGN scores higher overall (62/100 vs 59/100), backed by strong 21.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?